Company News from Basel-Stadt
Our section „Company News from Basel-Stadt“ regularly features and showcases a selection of corporate success stories from companies in Basel-Stadt.
BioVersys advances its two lead assets of ant-microbial resistance (AMR) candidates against infectious diseases into the first human clinical trials (Phase 1 Clinical Trial).
Cellestia Biotech has been awarded the Innosuisse Certificate and launches a new drug discovery programme to target Transcription Factors, which addresses unmet medical needs in cancer, autoimmune and inflammatory disorders.
NBE-Therapeutics announced to be acquired by Boehringer Ingelheim for EUR 1.18 billion. Further, NBE-Therapeutics expands access policy for NBE-002, a ROR1 targeting Antibody Drug Conjugate focusing on triple-negative breast cancer, providing an opportunity for patients to receive its investigational medicinal products outside of ongoing clinical trials.
Founded as a subsidiary of Swiss Rockets AG, Basel based Rocketvax aims to leverage the DNA synthesis technology acquired from the ETH Zurich spin-off Gigabases Switzerland AG to develop next generation of SARS-CoV-2 virus vaccines.
Roche receives CE mark approval for a new antigen nasal test called the Corona Rapid Test. In addition, Roche develops first orally administered drugs against Corona together with US biotech company Atea.